FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and can be used for treating pancreatic cancer in a patient. For this purpose, a patient is administered (i) an antibody capable of binding to CLDN18.2, and (ii) an agent which stabilizes or intensifies expression of CLDN18.2, wherein said cancer is characterized by cancer cells expressing CLDN18.2, and where (a) the antibody binds to CLDN18.2 and provides killing cells expressing CLDN18.2, wherein the antibody comprises an antibody heavy chain comprising an amino acid sequence presented by SEQ ID NO: 32, and an antibody light chain comprising an amino acid sequence presented by SEQ ID NO: 39, and (b) the agent is a nucleoside analogue selected from the group consisting of gemcitabine and its ester or salt.
EFFECT: group of inventions provides effective treatment of pancreatic cancer.
18 cl, 55 dwg, 21 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2014 |
|
RU2678700C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
